

Neurotech Appoints Dr. Bonni Goldstein as Chief Medical Advisor

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to announce the appointment of Dr. Bonni Goldstein as Chief Medical Advisor USA.

Dr. Goldstein will play a pivotal role in supporting the Company's regulatory strategy, clinical advancement and patient advocacy in the United States (US).

She is a highly respected physician with more than 25 years of clinical experience including 17 years focused exclusively on cannabinoid-based therapeutics. Dr. Goldstein is internationally recognised as a leading authority in the field and has personally treated thousands of children, including those with autism spectrum disorder, epilepsy, and Rett syndrome, making her one of the foremost experts globally in paediatric cannabinoid medicine.

Dr. Goldstein's appointment significantly enhances Neurotech's medical leadership. Her extensive experience in paediatric medicine and cannabinoid therapies, significantly bolsters Neurotech's strategic capability, particularly as the Company advances NTI164 through clinical development and towards commercialisation (subject to regulatory approval).

This high-profile appointment provides strong independent validation of Neurotech's innovative cannabinoid-based therapy, the Company's clinical and regulatory approach and highlights the significant potential NTI164 holds in treating neurological conditions, especially within paediatric populations. Dr. Goldstein's extensive network and recognition in medical, regulatory, advocacy and caregiver communities will further enhance the Company's visibility in the US market.

Commenting on the appointment, Neurotech CEO Anthony Filippis said: "We are thrilled to welcome Dr. Goldstein to Neurotech as Chief Medical Advisor USA. Her appointment represents a major step forward for the company. Dr. Goldstein's clinical and advocacy expertise, particularly in cannabinoid-based paediatric care, aligns perfectly with our mission to develop a safe, effective disease-modifying therapy for children with unmet medical needs."

Dr. Goldstein's contributions extend well beyond clinical care. She is a highly regarded author and thought leader in medical cannabis, with widely recognised books that have shaped both professional and public understanding of the field and her research has been featured in leading peer-reviewed journals. In recognition of her impact, she has received numerous accolades, including being named Medical Professional of the Year by Americans for Safe Access in 2017. Dr. Goldstein remains actively involved in research, education, and advocacy efforts to advance the responsible use of cannabinoid-based therapies.

Dr. Goldstein added, "I'm honoured to join Neurotech at such a pivotal time in its growth. I've seen first-hand the potential of cannabinoid therapies in paediatric patients, and I believe NTI164 holds significant promise. NTI164 is a novel neuro-modulatory therapy with unique bioactive compounds targeting neuroinflammation in neurological disorders, with excellent clinical data. I look forward to working with the team to help bring this important treatment to children and families in need."

Dr. Goldstein earned her Doctor of Medicine (MD) from Robert Wood Johnson Medical School at Rutgers University. She trained in paediatrics followed by a career in Paediatric Emergency Medicine. She is a licensed physician in California and an active member of numerous professional associations in the fields of integrative medicine and cannabinoid science.

This announcement has been authorised for release by the board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

About NTI164

NTI164 is a proprietary drug formulation derived from unique cannabis strains with a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. Clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.